红日药业: 董事会决议公告

Core Viewpoint - The company held its second board meeting of the ninth session on August 26, 2025, where several key resolutions were passed regarding the 2025 semi-annual report, fundraising, asset impairment provisions, and credit applications [2][5]. Group 1: Semi-Annual Report - The board approved the 2025 semi-annual report and its summary, affirming that the report accurately reflects the company's operational status without any false records or misleading statements [2][3]. Group 2: Fundraising Management - The board approved a special report on the management of fundraising, confirming compliance with relevant regulations and that there were no violations in the use of raised funds [3][4]. Group 3: Asset Impairment - The board approved the provision for asset impairment, stating that the decision was made based on a thorough analysis and evaluation, aligning with accounting standards and reflecting the company's financial status accurately [4][5]. Group 4: Credit Applications - The board approved a proposal for the company and its subsidiaries to apply for a total credit limit of up to RMB 2.1 billion from banks, which aims to support daily operations and project financing [5][6]. Group 5: Shareholder Meeting - The board proposed to convene the second extraordinary general meeting of shareholders on September 16, 2025, to discuss the approved resolutions [6].